Unicycive Therapeutics (UNCY) Equity Ratio (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Equity Ratio data on file, last reported at 0.59 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 45.16% year-over-year to 0.59; the trailing twelve-month figure through Mar 2026 stood at 0.59 (up 45.16% YoY), and the FY2025 full-year result was 0.61, up 161.91% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.59, down from 0.61 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.84 in Q1 2022 and bottomed at 0.85 in Q2 2023.
• The 5-year median for Equity Ratio is 0.23 (2024), against an average of 0.12.
• The widest annual swing landed in 2024, when Equity Ratio sank 508.76%; it then soared 264.92% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.17 in 2022, then tumbled by 62.31% to 0.27 in 2023, then surged by 187.42% to 0.23 in 2024, then jumped by 161.91% to 0.61 in 2025, then dropped by 4.74% to 0.59 in 2026.
• The last three Equity Ratio figures came in at 0.59 (Q1 2026), 0.61 (Q4 2025), and 0.74 (Q3 2025), per Business Quant data.

Peer Comparison